← Back to Browse

Kyntra Bio, Inc.

KYNB • Healthcare

73
Grade B
Compass
Current Price
$7.00
Market Cap
$50M

About Kyntra Bio, Inc.

Kyntra Bio, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993, and is headquartered in San Francisco, CA.

Quality Assessment

Kyntra Bio, Inc. is a above-average quality healthcare company with a Compass Score of 73. This stock shows solid fundamentals with room for improvement in some areas. Worth considering for a diversified portfolio.

Score Breakdown

The Compass Score is based on 6 quality factors identified by academic research.

Click any factor to see detailed metrics

Valuation Metrics

Click any metric for details

Technical Overview

Click any metric for details

Wall Street View

Consensus
N/A
Analysts
2
Price Target
๐Ÿ”’
Upside
๐Ÿ”’

Growth Projections

Projected EPS Growth
๐Ÿ”’
Projected Revenue Growth
๐Ÿ”’

Financial Health

Click any metric for details

Important Disclaimer

The Compass Score is for educational purposes only and does not constitute financial advice. Past performance does not guarantee future results. Always do your own research and consider consulting a financial advisor before making investment decisions.